Loading
Latest filing published 27 Feb 2024 for Enanta Pharmaceuticals INC, €43k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Nathaniel S. Gardiner (board member) discloses dealings in Enanta Pharmaceuticals Inc to SEC (Form 4). Between 19 November 2021 and 26 February 2024, the trades on record add up to 11 filings.
Every open-market trade on record is a sale: 1 sale worth €21k. Outside the open market, there are 8 share grants and 2 option exercises.
The latest filing, published on 27 February 2024, reports an option exercise of €43k in Enanta Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations